Pharmaceuticals

Non-Viral Gene Delivery Technologies Market Growth Projection: Expected to Surpass $9.26 Billion by 2030 at 15.1% CAGR

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-viral gene delivery technologies market from 2026–2035 with trusted insights from The Business Research Company

What growth pattern is forecast for the Non-Viral Gene Delivery Technologies Market size between 2026 and 2035?

The market size for non-viral gene delivery technologies has experienced rapid expansion in recent years. This sector is projected to grow from $4.57 billion in 2025 to $5.28 billion in 2026, at a compound annual growth rate (CAGR) of 15.5%. The historical growth can be attributed to factors such as reliance on viral delivery methods, limited availability of non-viral transfection reagents, a growing interest in gene therapy research, increasing use of plasmid dna and mrna delivery kits, and the adoption of electroporation and physical delivery techniques.

The market for non-viral gene delivery technologies is anticipated to experience significant expansion in the coming years, with projections indicating a rise to $9.26 billion by 2030, reflecting a compound annual growth rate (CAGR) of 15.1%. This growth during the forecast period is expected to stem from the advancement of lipid and polymer nanoparticles, the wider availability of pre-formulated nanoparticle technologies, increasing investment in gene editing and RNAi therapeutics, a growing demand for personalized gene therapy solutions, and the integration of high-throughput and automated delivery platforms. Noteworthy trends predicted for this period include the increased uptake of lipid-based and polymer-based non-viral delivery systems, the expansion of CRISPR and Cas9 gene editing applications, a heightened need for RNAi and DNA vaccine delivery platforms, the broadening of ex-vivo and in-vivo gene therapy research, and the development of cell-specific and targeted gene delivery reagents.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27367&type=smp

Which Drivers Are Impacting Market Performance In The Non-Viral Gene Delivery Technologies Market?

The rising necessity for personalized medicine is projected to stimulate the expansion of the non-viral gene delivery technologies market moving forward. Personalized medicine represents a healthcare strategy that customizes prevention, diagnosis, and treatment by factoring in an individual’s distinct genetic composition, lifestyle, and environmental influences. The heightened interest in personalized medicine is propelled by breakthroughs in genomic sequencing technologies, which facilitate more precise diagnoses, targeted therapeutic interventions, and improved treatment outcomes tailored for individual patients. This intensifying emphasis on personalized medicine is consequently boosting the demand for non-viral gene delivery technologies, as they provide safer and more adaptable means to deliver therapeutic genes suited to an individual’s genetic profile, without the inherent risks of viral vectors. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, stated that the Food and Drug Administration (FDA) sanctioned 16 novel personalized therapies for patients with rare diseases in 2023, a significant rise from 6 in 2022. Thus, the escalating demand for personalized medicine is actively fostering the growth of the non-viral gene delivery technologies market.

What Segment Types Are Examined In The Non-Viral Gene Delivery Technologies Market?

The non-viral gene delivery technologies market covered in this report is segmented –

1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles

2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo

3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles

4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression

5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses

Subsegments:

1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents

2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems

3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

Which Trends Are Influencing The Development Of The Non-Viral Gene Delivery Technologies Market?

Major companies within the non-viral gene delivery market are concentrating on developing advanced solutions like non-viral genetic medicine platforms to enhance the safety and efficiency of gene therapies. A non-viral genetic medicine platform is a technology that facilitates the introduction of therapeutic genes or nucleic acids into cells without the use of viruses, thereby mitigating immune reactions and safety concerns, and enabling precise and controlled gene therapy delivery for numerous diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company focused on developing genetic medicines, unveiled immune-quiet DNA (iqDNA). This innovative DNA represents an optimized version of their closed-ended DNA (ceDNA) that successfully evades innate immune detection, exhibiting cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered through their lipid nanoparticle (LNP) system. Owing to iqDNA’s superior tolerability, Generation Bio is advancing this as the primary DNA cargo in all its programs, including its leading hemophilia A program.

Who Are The Major Companies Operating In The Non-Viral Gene Delivery Technologies Market?

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-viral-gene-delivery-technologies-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Non-Viral Gene Delivery Technologies Market?

North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-viral gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Viral Gene Delivery Technologies Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27367&type=smp

Browse Through More Reports Similar to the Global Non-Viral Gene Delivery Technologies Market 2026, By The Business Research Company

Low Density Polyethylene Market Report 2026

https://www.thebusinessresearchcompany.com/report/low-density-polyethylene-global-market-report

Polyethylene Pipes Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyethylene-pipes-global-market-report

High Density Polyethylene Market Report 2026

https://www.thebusinessresearchcompany.com/report/high-density-polyethylene-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795